ArticleMethods in molecular biology (Clifton, N.J.)2026
Laboratory-Scale Production of Recombinant IgG Antibodies.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of hybridoma technology by Köhler and Milstein revolutionized the field of antibody research, paving the way for the creation of monoclonal antibodies. Due to their ability to specifically bind target molecules via antigen-antibody reactions, antibodies have become a major focus in therapeutic development. However, antibodies obtained from immunized animals such as mice may cause immunogenicity or side effects when administered to humans. While humanized mice offer a solution, their high-cost limits widespread adoption. Advances in genetic engineering technology have made it possible to create chimeric antibodies or humanized antibodies and have greatly reduced immunogenicity. In this chapter, we explain in detail a laboratory-scale protocol to produce recombinant IgG antibodies at the milligram scale, which is essential for in vivo research, using transient expression in CHO cells.
Indexed as
Identifiers
42108346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.